GlassScriptPhysician profile
Brenna Sommer
NPI 1497266811
$5,585.44
in general payments reported to CMS, 2019-2025
24 companies · $408 in 2025
The $408 reported for 2025 was more than what 76% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $325 · 2021: $3,773 · 2022: $329 · 2023: $445 · 2024: $305 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,158.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,559.88 | 2021 | |
| Abbvie INC. | $415.98 | 2021-2023 | Lo Loestrin Fe, Orilissa |
| Medical Device Business Services, INC. | $325.00 | 2019 | |
| Sage Therapeutics, LLC | $164.12 | 2024-2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $129.26 | 2022-2025 | |
| Mayne Pharma Commercial LLC | $120.80 | 2021-2025 | |
| Pfizer INC. | $105.33 | 2021-2025 | |
| Aspira Women'S Health INC | $98.90 | 2022-2024 | Ova1 |
| Astellas Pharma US INC | $97.84 | 2023-2025 | Veozah |
| Coopersurgical, INC. | $93.15 | 2021-2024 | Paragard T 380a, Paragard T 380a |
| Becton, Dickinson and Company | $92.42 | 2025 | |
| Therapeuticsmd, INC. | $61.48 | 2021 | |
| Meditrina | $48.65 | 2023 | |
| Myovant Sciences INC. | $38.88 | 2022 | |
| Sumitomo Pharma America, INC. | $38.86 | 2023-2025 | Myfembree |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $32.61 | 2022-2024 | |
| Pacira Pharmaceuticals Incorporated | $29.97 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.76 | 2023 | Xifaxan |
| Millicent US INC | $23.70 | 2025 | Intrarosa, Femring |
| Smith+Nephew, INC. | $21.24 | 2024 | Pico 14 |
| Exeltis, USA INC. | $19.69 | 2025 | Slynd |
| Boston Scientific Corporation | $15.90 | 2025 | Bulkamid |
| Hologic Sales and Service, LLC | $14.27 | 2025 | Thinprep 2000 Processor |
| Mimedx Group, INC. | $13.75 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brenna Sommer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.